Cargando…

Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor

INTRODUCTION: In severely neutropenic septic acute respiratory distress syndrome (ARDS) patients, macrophages and monocytes are the last potentially remaining innate immune cells. We have previously shown, however, a deactivation of the alveolar macrophage in neutropenic septic ARDS patients. In the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mokart, Djamel, Kipnis, Eric, Guerre-Berthelot, Pierre, Vey, Norbert, Capo, Christian, Sannini, Antoine, Brun, Jean-Paul, Blache, Jean-Louis, Mege, Jean-Louis, Blaise, Didier, Guery, Benoit P
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374582/
https://www.ncbi.nlm.nih.gov/pubmed/18282280
http://dx.doi.org/10.1186/cc6791
_version_ 1782154487280959488
author Mokart, Djamel
Kipnis, Eric
Guerre-Berthelot, Pierre
Vey, Norbert
Capo, Christian
Sannini, Antoine
Brun, Jean-Paul
Blache, Jean-Louis
Mege, Jean-Louis
Blaise, Didier
Guery, Benoit P
author_facet Mokart, Djamel
Kipnis, Eric
Guerre-Berthelot, Pierre
Vey, Norbert
Capo, Christian
Sannini, Antoine
Brun, Jean-Paul
Blache, Jean-Louis
Mege, Jean-Louis
Blaise, Didier
Guery, Benoit P
author_sort Mokart, Djamel
collection PubMed
description INTRODUCTION: In severely neutropenic septic acute respiratory distress syndrome (ARDS) patients, macrophages and monocytes are the last potentially remaining innate immune cells. We have previously shown, however, a deactivation of the alveolar macrophage in neutropenic septic ARDS patients. In the present study, we tried to characterize in vitro monocyte baseline cytokine production and responsiveness to lipopolysaccharide exposure. METHODS: Twenty-two consecutive patients with cancer were prospectively enrolled into a prospective observational study in an intensive care unit. All patients developed septic ARDS and were divided into two groups: neutropenic patients (n = 12) and non-neutropenic patients (n = 10). All of the neutropenic patients received granulocyte colony-stimulating factor whereas no patient in the non-neutropenic group received granulocyte colony-stimulating factor. We compared monocytes from neutropenic patients with septic ARDS with monocytes from non-neutropenic patients and healthy control individuals (n = 10). Peripheral blood monocytes were cultured, and cytokine levels (TNFα, IL-1β, IL-6, IL-10, and IL-1 receptor antagonist) were assayed with and without lipopolysaccharide stimulation. RESULTS: TNFα, IL-6, IL-10 and IL-1 receptor antagonist levels in unstimulated monocytes were lower in neutropenic patients compared with non-neutropenic patients. Values obtained in the healthy individuals were low as expected, comparable with neutropenic patients. In lipopolysaccharide-stimulated monocytes, both inflammatory and anti-inflammatory cytokine production were significantly lower in neutropenic patients compared with non-neutropenic patients and control individuals. CONCLUSION: Consistent with previous results concerning alveolar macrophage deactivation, we observed a systemic deactivation of monocytes in septic neutropenic ARDS. This deactivation participates in the overall immunodeficiency and could be linked to sepsis, chemotherapy and/or the use of granulocyte colony-stimulating factor.
format Text
id pubmed-2374582
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-23745822008-05-09 Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor Mokart, Djamel Kipnis, Eric Guerre-Berthelot, Pierre Vey, Norbert Capo, Christian Sannini, Antoine Brun, Jean-Paul Blache, Jean-Louis Mege, Jean-Louis Blaise, Didier Guery, Benoit P Crit Care Research INTRODUCTION: In severely neutropenic septic acute respiratory distress syndrome (ARDS) patients, macrophages and monocytes are the last potentially remaining innate immune cells. We have previously shown, however, a deactivation of the alveolar macrophage in neutropenic septic ARDS patients. In the present study, we tried to characterize in vitro monocyte baseline cytokine production and responsiveness to lipopolysaccharide exposure. METHODS: Twenty-two consecutive patients with cancer were prospectively enrolled into a prospective observational study in an intensive care unit. All patients developed septic ARDS and were divided into two groups: neutropenic patients (n = 12) and non-neutropenic patients (n = 10). All of the neutropenic patients received granulocyte colony-stimulating factor whereas no patient in the non-neutropenic group received granulocyte colony-stimulating factor. We compared monocytes from neutropenic patients with septic ARDS with monocytes from non-neutropenic patients and healthy control individuals (n = 10). Peripheral blood monocytes were cultured, and cytokine levels (TNFα, IL-1β, IL-6, IL-10, and IL-1 receptor antagonist) were assayed with and without lipopolysaccharide stimulation. RESULTS: TNFα, IL-6, IL-10 and IL-1 receptor antagonist levels in unstimulated monocytes were lower in neutropenic patients compared with non-neutropenic patients. Values obtained in the healthy individuals were low as expected, comparable with neutropenic patients. In lipopolysaccharide-stimulated monocytes, both inflammatory and anti-inflammatory cytokine production were significantly lower in neutropenic patients compared with non-neutropenic patients and control individuals. CONCLUSION: Consistent with previous results concerning alveolar macrophage deactivation, we observed a systemic deactivation of monocytes in septic neutropenic ARDS. This deactivation participates in the overall immunodeficiency and could be linked to sepsis, chemotherapy and/or the use of granulocyte colony-stimulating factor. BioMed Central 2008 2008-02-18 /pmc/articles/PMC2374582/ /pubmed/18282280 http://dx.doi.org/10.1186/cc6791 Text en Copyright © 2008 Mokart et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Mokart, Djamel
Kipnis, Eric
Guerre-Berthelot, Pierre
Vey, Norbert
Capo, Christian
Sannini, Antoine
Brun, Jean-Paul
Blache, Jean-Louis
Mege, Jean-Louis
Blaise, Didier
Guery, Benoit P
Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor
title Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor
title_full Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor
title_fullStr Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor
title_full_unstemmed Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor
title_short Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor
title_sort monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374582/
https://www.ncbi.nlm.nih.gov/pubmed/18282280
http://dx.doi.org/10.1186/cc6791
work_keys_str_mv AT mokartdjamel monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor
AT kipniseric monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor
AT guerreberthelotpierre monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor
AT veynorbert monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor
AT capochristian monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor
AT sanniniantoine monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor
AT brunjeanpaul monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor
AT blachejeanlouis monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor
AT megejeanlouis monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor
AT blaisedidier monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor
AT guerybenoitp monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor